Codexis Inc
NASDAQ:CDXS

Watchlist Manager
Codexis Inc Logo
Codexis Inc
NASDAQ:CDXS
Watchlist
Price: 4.61 USD 6.47% Market Closed
Market Cap: 375.2m USD
Have any thoughts about
Codexis Inc?
Write Note

Codexis Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Codexis Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Codexis Inc
NASDAQ:CDXS
PP&E Net
$24m
CAGR 3-Years
-12%
CAGR 5-Years
-5%
CAGR 10-Years
19%
Thermo Fisher Scientific Inc
NYSE:TMO
PP&E Net
$9.4B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
15%
Danaher Corp
NYSE:DHR
PP&E Net
$6B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
11%
Mettler-Toledo International Inc
NYSE:MTD
PP&E Net
$790.4m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
PP&E Net
$1.6B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
4%
IQVIA Holdings Inc
NYSE:IQV
PP&E Net
$772m
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
15%
No Stocks Found

Codexis Inc
Glance View

Market Cap
375.1m USD
Industry
Life Sciences Tools & Services

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 261 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and sells enzymes and other proteins. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The firm has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. The company also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The firm is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

CDXS Intrinsic Value
2.92 USD
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Codexis Inc's PP&E Net?
PP&E Net
24m USD

Based on the financial report for Sep 30, 2024, Codexis Inc's PP&E Net amounts to 24m USD.

What is Codexis Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
19%

Over the last year, the PP&E Net growth was -18%. The average annual PP&E Net growth rates for Codexis Inc have been -12% over the past three years , -5% over the past five years , and 19% over the past ten years .

Back to Top